| Trial ID: | L0645 |
| Source ID: | NCT04215445
|
| Associated Drug: |
Empagliflozin 25 Mg
|
| Title: |
Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetic Retinopathy|Chronic Kidney Diseases|Diabetes Mellitus
|
| Interventions: |
DRUG: Empagliflozin 25 MG|DEVICE: OCT-A
|
| Outcome Measures: |
Primary: Comparison of change in fovea avascular zone within retina of proteinuric and non-proteinuric chronic kidney disease patients treated with SGLT2-inhibitor, Change in fovea vascular zone (FAZ) size (um2) from Baseline using Optical Coherence Tomography Angiography (OCT-A) post-SGLT-2 treatment, After 28 days of treatment|Comparison of change in retinal and choroidal vessel density in proteinuric and non-proteinuric chronic kidney disease patients treated with SGLT2-inhibitor, Change in vessel density (mm-1) from Baseline using Optical Coherence Tomography Angiography (OCT-A) post-SGLT-2 treatment, After 28 days of treatment|Comparison of change in retinal and choroidal vascular perfusion density in proteinuric and non-proteinuric chronic kidney disease patients treated with SGLT2-inhibitor, Change in perfusion density from Baseline using Optical Coherence Tomography Angiography (OCT-A) post-SGLT-2 treatment, After 28 days of treatment |
|
| Sponsor/Collaborators: |
Sponsor: National University of Malaysia
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
90
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-12-01
|
| Completion Date: |
2020-08
|
| Results First Posted: |
|
| Last Update Posted: |
2020-01-02
|
| Locations: |
UKM Medical Centre, Kuala Lumpur, Wilayah Persekutuan, 56000, Malaysia
|
| URL: |
https://clinicaltrials.gov/show/NCT04215445
|
